Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 27, 2018 | June 29, 2018 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 12, 2018 | June 14, 2018 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | October 02, 2026 | October 06, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director · Chief Executive Officer | February 17, 2026 | February 19, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, COO | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 27, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27 | Direct | 15,000 |
Reported balance
After 2018-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
INFINITY PHARMACEUTICALS, INC.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,845 |
Reported balance
After 2018-06-12 transaction · row 1
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845 F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 4,000 |
Reported balance
After 2018-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000 F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.
F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Solid Biosciences Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,585 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585 F1: Restricted stock units convert to common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,440 |
Reported balance
After 2026-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440 F1: Restricted stock units convert to common stock on a one-for-one basis. F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert to common stock on a one-for-one basis.
F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
Stoke Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16 | Direct | 193,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000 F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15 | Direct | 129,000 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,699 |
Ending reported balance
After 2018-06-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074 Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89). F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20 | Direct | 10,625 |
Reported balance
After 2018-06-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625 F5: The option vests in 16 quarterly installments from 7/21/2015. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,306 |
Reported balance
Holding disclosure · report date 2018-06-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,306 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).
F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).
F5: The option vests in 16 quarterly installments from 7/21/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 9, 2023 01:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-014998 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F3 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 03, 2023 Filed Jun 9, 2023 01:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 15,569 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014998 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,709 Underlying: Common Stock · 15,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| April 03, 2023 Filed Jun 9, 2023 01:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 15,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014998 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 62,278 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,278 Underlying: Common Stock · 62,278 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs"). F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,796 | $0.00 Strike: $5.62 | $0.00 |
DisclosureSEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,796 Underlying: Common Stock · 70,796 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vested in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vested in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-001134 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000899243-22-038696 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2032-12-13 F2 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 23:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 13,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037693 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,380 F1 · price: The reporting person acquired 13,172 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:50 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 24,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052331 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,312 Underlying: Common Stock · 24,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:50 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 24,312 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-052331 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 03, 2022 Filed Jul 6, 2022 20:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 24,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041164 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,624 Underlying: Common Stock · 24,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full. Read SEC document |
| July 03, 2022 Filed Jul 6, 2022 20:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 24,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041164 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 01:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001562180-22-005317 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-20 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035463 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 03, 2022 Filed Apr 5, 2022 20:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 24,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023040 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,937 Underlying: Common Stock · 24,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full. Read SEC document |
| April 03, 2022 Filed Apr 5, 2022 20:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 24,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-023040 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 97,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,250 Underlying: Common Stock · 97,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 194,500 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,500 Underlying: Common Stock · 194,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: This option was granted on January 3, 2022 pursuant to a services agreement between the reporting person and the Issuer and will vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 12,530 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001562180-21-004483 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,530 Underlying: Common Stock · 12,530 shares Expires 2031-06-22 F1 · derivative.exercise_date: The option was granted pursuant to a consulting agreement effective June 23, 2021 (the "Effective Date"). The option will vest as to 1/12 of the underlying shares of common stock on the first day of each month beginning on August 1, 2021, with the balance of then-unvested shares to vest one year after the Effective Date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001209191-21-041938 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:01 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 25,060 | $11.50 Strike: $11.50 | $288,190.00 |
DisclosureSEC source: 0001562180-21-003018 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,060 Underlying: Common Stock · 25,060 shares Expires 2031-04-26 F1 · derivative.exercise_date: The options will vest as to 25% of the underlying shares of common stock on April 27, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 389,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0001209191-21-001966 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,000 Underlying: Common Stock · 389,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option was granted on January 4, 2021 and will vest in equal quarterly installments beginning three months from the date of the grant with the final installment vesting date being the later of the completion of a specified service requirement under his consulting agreement or 12 months from the date of the grant, subject to continued service as a director or consultant, and in the event of a change in control, the vesting schedule of the option will accelerate in full. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 270,270 | $3.70 | $999,999.00 |
DisclosureSEC source: 0001209191-20-063218 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,270 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037594 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2020 and will vest in equal quarterly installments beginning three months from the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 11:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001209191-20-024599 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-04-15 F1 · derivative.exercise_date: This option was granted on April 15, 2020 and vests as to one-third of the total number of shares on each of the next three anniversaries of the grant date. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,375 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-18-041074 · doc4.xml · derivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 23,375 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/21/2015. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18,634 | $166.57 | $3,103,865.38 |
DisclosureSEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67). Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,741 | $165.22 | $783,308.02 |
DisclosureSEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,333 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 23,375 | $131.89 | $3,082,928.75 |
DisclosureSEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $28.15 | $0.00 |
DisclosureSEC source: 0001209191-18-039999 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-18-039524 · doc4.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,250 | $160.00 | $680,000.00 |
DisclosureSEC source: 0001209191-18-039524 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $109.14 | $463,845.00 |
DisclosureSEC source: 0001209191-18-039524 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-18-038543 · doc4.xml · derivative · entry 5 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercises and sales pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 5/31/2018. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0001209191-18-038543 · doc4.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercises and sales pursuant to a 10b5-1 plan. F3 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 6/22/2010. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 25,000 | $31.42 | $785,567.50 |
DisclosureSEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Exercises and sales pursuant to a 10b5-1 plan. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $31.15 to $31.55 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 15,000 | $13.80 | $207,000.00 |
DisclosureSEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercises and sales pursuant to a 10b5-1 plan. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 10,000 | $25.45 | $254,500.00 |
DisclosureSEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercises and sales pursuant to a 10b5-1 plan. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 08:34 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-18-016532 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-06-12 F3 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 08:34 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-18-016532 · doc4.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 08:34 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantCommon Stock | 22,857 | $1.75 | $39,999.75 |
DisclosureSEC source: 0000899243-18-016532 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,845 F1 · shares: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 217 | $155.78 | $33,804.26 |
DisclosureSEC source: 0001209191-18-030604 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,941 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-030207 · doc4.xml · derivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,358 Underlying: Common Stock · 1,941 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-030207 · doc4.xml · derivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,086 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,096 | $155.00 | $634,880.00 |
DisclosureSEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,941 | $86.52 | $167,935.32 |
DisclosureSEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 4, 2018 17:50 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-18-028179 · doc4.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F4 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 05/21/2009. Read SEC document |
| May 02, 2018 Filed May 4, 2018 17:50 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 6,323 | $23.86 | $150,897.13 |
DisclosureSEC source: 0001209191-18-028179 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $23.7750 to $24.0500 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.